Pharmacology of apolipoprotein A-I.
The role of HDL and its main protein component the apolipoprotein A-I as being antiatherogenic is well established. Experimental data give support for the involvement of at least three different types of mechanism: (1) the reverse cholesterol transport, (2) anti-inflammatory mechanisms and (3) antithrombotic mechanisms. Depending upon the stage and type of atherosclerosis, different mechanisms may be more or less important. Knowledge of pharmacology of apolipoprotein A-I has strongly increased during past years and clinical studies have started with infusions of apolipoprotein A-I phospholipid complexes.
Andersson
L O
LO
Cardiocon AB, Knivsta, Sweden.
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D000924:Anticholesteremic Agents / Q000494:pharmacology; D000925:Anticoagulants / Q000494:pharmacology; D016632:Apolipoprotein A-I / Q000494:pharmacology*; D001161:Arteriosclerosis / Q000378:metabolism*; D001692:Biological Transport; D002784:Cholesterol / Q000378:metabolism; D006801:Humans; D008075:Lipoproteins, HDL / Q000378:metabolism*; D010743:Phospholipids / Q000494:pharmacology*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000924:Anticholesteremic Agents; D000925:Anticoagulants; D016632:Apolipoprotein A-I; D008075:Lipoproteins, HDL; D010743:Phospholipids; C080631:apolipoprotein A-I Milano; D002784:Cholesterol